Download
s10741-021-10106-9.pdf 555,44KB
WeightNameValue
1000 Titel
  • New antidiabetic therapy and HFpEF: light at the end of tunnel?
1000 Autor/in
  1. Tadic, Marijana |
  2. Sala, Carla |
  3. Saeed, Sahrai |
  4. Grassi, Guido |
  5. Mancia, Giuseppe |
  6. Rottbauer, Wolfang |
  7. Cuspidi, Cesare |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-04-11
1000 Erschienen in
1000 Quellenangabe
  • 27(4):1137-1146
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s10741-021-10106-9 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9197886/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • New antidiabetic therapy that includes sodium-glucose co-transporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 receptor (GLP-1R) agonists, and dipeptidyl peptidase 4 (DPP-4) inhibitors showed significant benefit on cardiovascular outcomes in patients with and without type 2 diabetes mellitus, and this was particularly confirmed for SGLT2 inhibitors in subjects with heart failure (HF) with reduced ejection fraction (HFrEF). Their role on patients with HF with preserved ejection fraction (HFpEF) is still not elucidated, but encouraging results coming from the clinical studies indicate their beneficial role. The role of GLP-1R agonists and particularly DPP-4 inhibitors is less clear and debatable. Findings from the meta-analyses are sending positive message about the use of GLP-1R agonists in HFrEF therapy and revealed the improvement of left ventricular (LV) diastolic function in HFpEF. Nevertheless, the relevant medical societies still consider their effect as neutral or insufficiently investigated in HF patients. The impact of DPP-4 inhibitors in HF is the most controversial due to conflicting data that range from negative impact and increased risk of hospitalization due to HF, throughout neutral effect, to beneficial influence on LV diastolic dysfunction. However, this is a very heterogeneous group of medications and some professional societies made clear discrepancy between saxagliptin that might increase risk of HF hospitalization and those DPP-4 inhibitors that have no effect on hospitalization. The aim of this review is to summarize current clinical evidence about the effect of new antidiabetic medications on LV diastolic function and their potential benefits in HFpEF patients.
1000 Sacherschließung
lokal Sodium-Glucose Transporter 2 Inhibitors/therapeutic use [MeSH]
lokal Heart failure
lokal Diabetes Mellitus, Type 2/complications [MeSH]
lokal GLP-1 receptor agonists
lokal Humans [MeSH]
lokal Diabetes Mellitus, Type 2/drug therapy [MeSH]
lokal Left ventricular
lokal Ventricular Dysfunction, Left [MeSH]
lokal Diastolic function
lokal Dipeptidyl-Peptidase IV Inhibitors/therapeutic use [MeSH]
lokal DPP-4 inhibitors
lokal Article
lokal Stroke Volume [MeSH]
lokal Hypoglycemic Agents/therapeutic use [MeSH]
lokal Heart Failure/etiology [MeSH]
lokal SGLT2 inhibitors
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0002-6235-5152|https://frl.publisso.de/adhoc/uri/U2FsYSwgQ2FybGE=|https://frl.publisso.de/adhoc/uri/U2FlZWQsIFNhaHJhaQ==|https://frl.publisso.de/adhoc/uri/R3Jhc3NpLCBHdWlkbw==|https://frl.publisso.de/adhoc/uri/TWFuY2lhLCBHaXVzZXBwZQ==|https://frl.publisso.de/adhoc/uri/Um90dGJhdWVyLCBXb2xmYW5n|https://frl.publisso.de/adhoc/uri/Q3VzcGlkaSwgQ2VzYXJl
1000 Hinweis
  • DeepGreen-ID: 0931bffdda5146e4a7d2321f78d2f107 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
  1. New antidiabetic therapy and HFpEF: light at the end of tunnel?
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6444945.rdf
1000 Erstellt am 2023-04-27T14:59:59.662+0200
1000 Erstellt von 322
1000 beschreibt frl:6444945
1000 Zuletzt bearbeitet 2023-10-20T14:21:36.789+0200
1000 Objekt bearb. Fri Oct 20 14:21:36 CEST 2023
1000 Vgl. frl:6444945
1000 Oai Id
  1. oai:frl.publisso.de:frl:6444945 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source